MAPT and Alzheimer disease: A systematic assessment using mouse and human organoid models revealed that semaglutide treatment decreased levels of Aβ, p-tau, and glial fibrillary acidic protein (GFAP) and increased oxytocin/neurophysin I prepropeptide (OXT) expression in the AD-brain organoid model [267].